Equipment (2 CFR 200.1 Definition)

A Medical Monitor is the physician (or, in some organizations, another appropriately qualified clinician) designated by a clinical trial sponsor or the sponsor’s Contract Research Organization (CRO) to provide ongoing, cross-site medical and safety oversight of a study. The role is operationally defined by three features together, not any one alone: (1) medical qualification — the person holds a medical degree and relevant clinical expertise in the therapeutic area under study; (2) sponsor-side placement — the Medical Monitor works for or is contracted by the sponsor/CRO, not by an individual investigational site, and has no direct treatment relationship with any trial participant; and (3) safety-judgment scope — the Medical Monitor reviews adverse events (AEs) and serious adverse events (SAEs) as they accumulate across all sites, assesses causality and expectedness, answers investigators’ medical eligibility and protocol-interpretation questions, and flags safety signals that may require a protocol amendment, a dose modification, or referral to a Data and Safety Monitoring Board (DSMB). A role that lacks any one of these three — a non-physician performing safety triage, a site-based physician overseeing only their own participants, or a sponsor employee with no defined AE-causality responsibility — is not functioning as a Medical Monitor in the operational sense used in trial staffing plans and monitoring plans.

Medical Monitor vs. Principal Investigator

The Principal Investigator (PI) is site-based: the PI (or a delegated co-investigator/sub-investigator) personally examines and treats enrolled participants at their site, makes the initial AE/SAE report and initial causality assessment for events they observe, and signs the FDA Form 1572 investigator statement of responsibility for that site. The Medical Monitor sits on the sponsor/CRO side of the trial, has no participant-care relationship, and reviews AEs and SAEs in aggregate across every site, not just one. The two roles are complementary, not interchangeable: the PI’s causality assessment for an individual event is one input the Medical Monitor weighs alongside the emerging pattern across the whole study. The same physician does not normally hold both roles on the same trial, because doing so would remove the independent, cross-site check the Medical Monitor function exists to provide.

Medical Monitor vs. Data and Safety Monitoring Board (DSMB)

A DSMB (also called a Data Monitoring Committee, DMC) is a standing committee, external to and independent of the sponsor, that periodically reviews accumulating efficacy and safety data — often unblinded — at pre-specified intervals and can recommend a trial continue, be modified, or stop. A Medical Monitor is a single individual, typically sponsor- or CRO-affiliated (not independent of the sponsor in the way a DSMB is), who performs continuous, first-line safety review rather than periodic, scheduled review. In practice the Medical Monitor is often the person who prepares the safety data package the DSMB reviews, and who may recommend that an ad hoc DSMB meeting be convened when a safety signal warrants it — the two functions are sequential and complementary, not overlapping.

Medical Monitor vs. Clinical Research Associate (CRA)

A Clinical Research Associate (CRA) monitors a trial’s operational and data-quality conduct: verifying source-data-to-case-report-form accuracy, confirming regulatory documents are current, and checking protocol adherence at assigned sites. A CRA is not required to hold a medical degree and does not make medical judgment calls — a CRA identifies that an AE was recorded or a protocol deviation occurred, but refers any question requiring clinical interpretation (is this event related to the study drug? does this lab value meet the eligibility criteria?) to the Medical Monitor or the site investigator. The two roles frequently work together: a CRA flags an issue during a site visit, and the Medical Monitor supplies the medical judgment needed to resolve it.

Regulatory and guidance basis

Neither the ICH E6(R2) Good Clinical Practice guideline nor its 21 CFR Part 312 counterpart in FDA regulation uses “Medical Monitor” as a formally defined glossary term the way they define “Investigator” or “Sponsor.” The role is nonetheless a de facto requirement of the sponsor’s safety obligations: 21 CFR 312.32 requires the sponsor to have qualified medical personnel review and evaluate all safety information, and ICH E6 assigns the sponsor overall responsibility for ongoing safety evaluation throughout a trial (E6(R2) §5.16-5.18). Industry practice, FDA guidance on sponsor oversight, and the newer ICH E6(R3) revision discuss the underlying function more explicitly than E6(R2) did, but “Medical Monitor” itself remains an industry-standard job title for how sponsors satisfy that regulatory obligation, rather than a term with one single regulatory definition — trial-specific monitoring plans and safety management plans are where a given study’s Medical Monitor responsibilities, authority, and escalation pathway are actually documented.

Core responsibilities

• First-line, ongoing review of AEs and SAEs reported from all sites, including causality and expectedness assessment
• Detecting emerging safety signals across the aggregate dataset and escalating them to the sponsor’s safety team or a DSMB
• Answering site investigators’ medical questions about participant eligibility, dose modification, or protocol interpretation
• Reviewing protocol deviations and amendments for their safety implications
• Contributing medical input to the protocol, investigator’s brochure, and informed consent documents before and during the trial
• Providing on-call medical support to investigational sites, often on a 24/7 basis for time-sensitive safety questions

Examples

Example 1. In a sponsor-run Phase III oncology trial, a board-certified oncologist serves as Medical Monitor. Every SAE report from every site crosses their desk; they assign a causality determination (related, possibly related, or unrelated to the investigational drug) and track whether a pre-specified dose-limiting-toxicity boundary has been reached across the accumulating dataset.

Example 2. A CRO running a multi-site medical-device trial retains a physician — employed by the CRO rather than the sponsor — as Medical Monitor. That physician is on call to answer site investigators’ eligibility questions (for example, whether a participant with a borderline lab value still qualifies under the protocol’s inclusion criteria) and reviews every protocol deviation report that has a possible safety dimension.

Counter-example. A site’s Principal Investigator, who personally examines participants, prescribes the investigational product, and files the initial AE reports for their own site, is not acting as a Medical Monitor even though both roles are physicians making medical judgments. The PI has a direct participant-care relationship and a single-site scope defined by the FDA Form 1572; the Medical Monitor role specifically requires the absence of a direct-care relationship and a cross-site scope, which is why the same person does not typically fill both roles on one trial.

Related terms

See also: Principal Investigator (PI), Co-investigator, Data and Safety Monitoring Board (DSMB), Clinical Research Associate (CRA), Contract Research Organization (CRO), Adverse Event (AE), Protocol Deviation, ICH E6(R2).

Frequently Asked Questions

What is the equipment threshold under 2 CFR 200.1?

Under 2 CFR 200.1, an item is “Equipment” only if it has a useful life of more than one year and a per-unit acquisition cost that equals or exceeds the lesser of the recipient institution’s own capitalization level or $10,000. The $10,000 figure applies to federal awards issued on or after October 1, 2024; it replaced a $5,000 default that applied to earlier awards.

What’s the difference between equipment and supplies under 2 CFR 200.1?

2 CFR 200.1 defines “Supplies” as all tangible personal property other than Equipment, including computing devices that fall below the Equipment cost threshold regardless of how long they’ll last. An item counts as Equipment only if it meets both the useful-life-over-one-year test and the cost test; if it fails either one, it’s a Supply — expensed through ordinary purchasing records rather than tagged and entered into the institution’s asset-management system.

Does NIH use a different equipment threshold than 2 CFR 200.1?

No. NIH does not maintain its own definition of Equipment — as an HHS operating division, it applies the same government-wide 2 CFR 200.1 definition and threshold to its own grants, and the NIH Grants Policy Statement incorporates 2 CFR Part 200 by reference rather than restating a competing figure. An “NIH-specific” equipment definition found elsewhere is usually just an outdated source still citing the superseded $5,000 figure.

Why do some sources still cite $5,000 as the equipment threshold instead of $10,000?

A 2024 revision to 2 CFR 200 raised the government-wide default capitalization floor for Equipment from $5,000 to $10,000, effective for federal awards issued on or after October 1, 2024. Older institutional policy pages, training materials, and secondary sources written before that change often still show $5,000, so it’s worth checking the source’s date and the issuance date of the specific award in question.

Can an institution use a capitalization threshold other than $10,000?

Yes, but only downward. 2 CFR 200.1 sets the threshold at the lesser of the institution’s own capitalization level or $10,000, so an institution with a lower internal policy (e.g., $5,000) must apply its own lower figure to federal awards. An institution cannot set its threshold above $10,000 to keep sub-$10,000 items out of Equipment treatment — $10,000 operates as a ceiling.

What happens to equipment when a federal award ends?

Equipment disposition is governed by 2 CFR 200.313, which sets rules for sale, transfer, or retention of the item. Above certain fair-market-value thresholds, disposition may require federal agency instructions or return of the government’s proportional interest in the item’s value.